Endoscopic Resection of Esophageal Lymphangioma Incidentally Discovered

por Scarpis, M., De Monti, M., Pezzotta, M. G., Sonnino, D., Mosca, D., Milani, M.
Publicado 1998

Class 1 integron and Imipenem Resistance in Clinical Isolates of Pseudomonas aeruginosa: Prevalence and Antibiotic Susceptibility

por Yousefi, S, Nahaei, MR, Farajnia, S, Ghojazadeh, M, Akhi, MT, Sharifi, Y, Milani, M, Ghotaslou, R
Publicado 2010

Antiproliferative effect of mifepristone (RU486) on human neuroblastoma cells (SK-N-SH): in vitro and in vivo studies

por Casulari, L.A., Dondi, D., Pratesi, G., Piva, F., Milani, M., Piccolella, M., Maggi, R.
Publicado 2020

The vortex-driven dynamics of droplets within droplets

por Tiribocchi, A., Montessori, A., Lauricella, M., Bonaccorso, F., Succi, S., Aime, S., Milani, M., Weitz, D. A.
Publicado 2021

Serum Zinc Levels in Children and Adolescents with Type-1 Diabetes Mellitus

por Estakhri, M, Djazayery, A, Eshraghian, MR, Majdzadeh, R, Jalali, M, Karamizadeh, Z, Chamari, M, Milani, M Peyrovi
Publicado 2011

High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X(L) in chronic myeloid leukemia

por Lucas, C M, Milani, M, Butterworth, M, Carmell, N, Scott, L J, Clark, R E, Cohen, G M, Varadarajan, S
Publicado 2016

P04 MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

por Fazio, F., Lapietra, G., Limongi, M. Z., Intoppa, S., Milani, M. L., Piciocchi, A., Martelli, M., Guarini, A., Foà, R., De Propris, M. S., Petrucci, M. T.
Publicado 2023

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

por Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A L, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A
Publicado 2008

P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY

por Natoni, A., Cerreto, M., De Propris, M. S., Petrucci, M. T., Del Giudice, I., Intoppa, S., Milani, M. L., Kirkham-McCarthy, L., Henderson, R., Swan, D., O’Dwyer, M., Guarini, A., Foà, R.
Publicado 2022

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy

por Koukourakis, M I, Giatromanolaki, A, Bottini, A, Cappelletti, M R, Zanotti, L, Allevi, G, Strina, C, Ardine, M, Milani, M, Brugnoli, G, Martinotti, M, Ferrero, G, Bertoni, R, Ferrozzi, F, Harris, A L, Generali, D
Publicado 2014

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

por Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D
Publicado 2013

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

por Berruti, A, Bitossi, R, Gorzegno, G, Bottini, A, Generali, D, Milani, M, Katsaros, D, Rigault de la Longrais, I A, Bellino, R, Donadio, M, Ardine, M, Bertetto, O, Danese, S, Sarobba, M G, Farris, A, Lorusso, V, Dogliotti, L
Publicado 2005

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

por Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D
Publicado 2015